Loading clinical trials...

Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGEARLY_PHASE1

Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings

NCT07348172•Stanford University

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate whether medications used in peri-procedural clinical settings can modulate drug liking.

Detailed Description

Specifically, we aim to measure differences in drug liking with a VAS (0 - 100) questionnaire. Additionally, we will monitor neural activity recording a frontal electroencephalogram (EEG) to detect changes in brain signals associated with opioid drug effects. By comparing behavioral and neurophysiological data across treatment and control groups, this study seeks to explore the therapeutic potential of this medication.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•American Society of Anesthesiologists (ASA) physical status classification of I, II or III
•Candidates who are expected to receive fentanyl up to 3 mcg/kg IBW for their scheduled for surgery or procedure

Exclusion Criteria

•Craniofacial abnormalities
•Known or suspected difficult intubation or mask ventilation
•Known or suspected need for rapid sequence induction and intubation
•Allergies or hypersensitivities to amisulpride or fentanyl
•Clinically significant pulmonary disease, such as chronic obstructive lung disease requiring long-term oxygen therapy, or other conditions that, in the study team's judgment, may increase the risk of severe respiratory depression with opioid administration
•History of long QT syndrome
•Any heart rhythm other than normal sinus rhythm (including but not limited to atrial fibrillation, atrial flutter, paced rhythms, ventricular tachycardia, or any supraventricular tachycardia)
•History of Torsades de Pointes
•History of psychosis
•History of movement disorders e.g. Parkinson's Disease
+9 more criteria

Locations (1)

Stanford Hospital

Palo Alto, California, United States

Key Dates

Start Date

March 1, 2026

Primary Completion Date

March 31, 2027

Completion Date

March 31, 2028

Last Updated

January 16, 2026

Enrollment

100

ESTIMATED participants

Conditions

Drug Liking

Interventions

Amisulpride

DRUG

Placebo

DRUG

Contacts

Patrick L Purdon, PhD

CONTACT

6507367331 ppurdon@stanford.edu

Characterizing the EEG Signature of Fentanyl and Its Association With Drug Liking

NCT06699953

Brain Activity Related to Opioid AdministrationBrain Activity Related to Drug Liking

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 16, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions